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A B S T R A C T
Nonconvulsive status epilepticus (NCSE) is a heterogeneous disorder with different seizure types and
diverse etiologies, and is mainly characterized by altered consciousness. The recognition of NCSE is more
challenging than generalized convulsive SE, and diagnosis and treatment are often delayed. Therefore,
some cases can evolve into refractory SE and become pharmacoresistant even with GABAergic
anesthetics. Herein we report the successful clinical experience of pharmacoresistant complex partial SE
treated with ketamine. An elderly woman was profoundly stuporous and had relentless clonic
movements of the right hand and forearm. Electroencephalography revealed repetitive periodic
lateralized epileptiform discharges (PLEDs). There was a poor clinical response to standard
anticonvulsants and GABAergic anesthetics. Both the clinical and electroencephalographic SE were
controlled after intravenous ketamine therapy. Rebound refractory NCSE occurred about six days after
discontinuing the intravenous ketamine, which was successfully terminated by oral ketamine treatment.
There were no adverse effects observed.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Nonconvulsive status epilepticus (NCSE) often manifests as
altered consciousness accompanied with subtle focal motor
twitches or ambiguous behavior changes, and the diagnosis has
to be based on electroencephalography (EEG).1,2 It is easily
misdiagnosed clinically without evidence of continuous epilepti-
form activities on EEG, and attempts to terminate NCSE are
frequently delayed. Unfortunately, a number of such cases with
prolonged and persistent seizures will become malignant and self-
sustaining refractory to standard pharmacotherapy. To date, there
is no consensus on treating comatose patients with refractory
NCSE, and the treatment mostly follows the guidelines on
management of refractory generalized convulsive SE (GCSE).3–5
When anesthetic agents involving g-aminobutyric acid (GABA)
receptors fail to stop ongoing seizures and prevent their
recurrence, a non-competitive N-methyl-D-aspartate (NMDA)
antagonist, ketamine, has been successfully used in animal models
and a few human cases, based on the theory of an imbalance of* Corresponding author at: Department of Neurology, Chi-Mei Medical Center,
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seizures are continued.6–8 Ketamine is currently used as an
anesthetic agent for short operations, pediatric or veterinary
surgeries, and also for chronic pain control. In the past, the clinical
use of ketamine in control refractory SE was mostly via an
intravenous route, and oral ketamine therapy has been documen-
ted only in pediatric patients with NCSE.9 Herein we report the
successful experience of oral ketamine use in terminating
refractory complex partial status epilepticus in an elderly patient.
2. Case report
A 76-year-old woman was admitted to our neurological ward for
prolonged disturbed consciousness over 12 h after cessation of a
generalized convulsion by intravenous (IV) lorazepam at the
emergency unit. She had recurrent ischemic, hemorrhagic strokes
and bilateral traumatic subdural hemorrhages before this admis-
sion, and vascular dementia and a dependent life for 1 year. She had
complex partial seizures characterized by right hand twitches and
blank staring for 2 months, and used carbamazepine intermittently.
Upon admission, she was in a profound stuporous state and had
persistent clonic twitches or choreatic movements of her right hand
and forearm at a frequency of about 1–2 Hz. An emergency
electroencephalogram (EEG) showed periodic lateralized epilepti-
form discharges (PLED) with high-amplitude polyspikes recurringvier Ltd. All rights reserved.
Fig. 1. Electroencephalographic recordings during the time course of treatment. (a) Before GABAergic anesthetic treatment, periodic lateralized epileptiform discharges were
seen over the left hemisphere with the highest amplitude on the left anterior frontal area. (b) After propofol-induced coma, the burst period of burst–suppression patterns
consisted of lateral periodic epileptic discharges over the left anterior frontal area. (c) After intravenous ketamine with a cumulative dose of about 2500 mg, PLEDs
disappeared and diffuse low amplitude slow waves were seen on the left hemisphere. (d) Reappearance of PLEDs on the left hemisphere after withdrawal of intravenous
ketamine. (e) After oral ketamine with a cumulative oral dose of about 1500 mg, diffuse irregular theta waves on both hemispheres were seen.
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left anterior frontal area (Fig. 1a). Brain magnetic resonance images
(MRI) revealed old ischemic and hemorrhagic lesions, residual
subdural hematoma and diffuse brain atrophy. A series of
hematological, biochemistry and hormone studies revealed only a
urinary tract infection. Under the impression of complex partial
status epilepticus (CPSE) provoked by systemic infection and
inadequate medicine control, she was ﬁrst treated with intravenous
(IV) valproic acid (bolus of 40 mg/kg, then 400 mg every 6 h with a
blood level reaching 98 mg/mL) with no clinical improvement.
Midazolam anesthesia (initial dose of 0.4 mg/kg/h) was added soon
after her airway had been protected, but it failed to reach burst–
suppression (BS) on EEG even under a higher dosage (up to 1 mg/kg/
h). Oral levetiracetam (2000 mg/d/os) on day 2 and IV phenytoin
(bolus of 20 mg/kg, then 300 mg/d) on day 3 were tried, however SE
continued. In order to achieve a better suppression of clinical and
EEG seizure activities, propofol anesthesia (up to 5 mg/kg/h) was
substituted on day 4. The patient fell into a deeper coma state but
there were still relentless subtle focal motor seizures of the right
hand, and meanwhile her EEG showed near-total suppression and
intermittent bursts of high-voltage spikes at the left frontal area
(Fig. 1b). From the initiation of propofol treatment, remarkable
hypotension and stagnant bowel movements were observed, and aninotropic agent had to be given to stabilize the hemodynamic
condition. The systemic side effects worsened and propofol
anesthesia was withdrawn on day 6. Because thiopental was not
available and the generic brand of phenobarbital in our hospital
could not be given through an IV route, intramuscular (IM)
phenobarbital was administered (100 mg every 4 h) after propofol
had been stopped. In the meantime, IV valproic acid and lamotrigine
(slow titrating dose starting with 50 mg/d/os) were maintained, and
other standard anticonvulsants including oral carbamazepam
(600 mg/d/os) and vigabatrin (2000 mg/d/os) were ineffective.
Unfortunately, acute hepatitis with elevated liver enzymes and
skin rash developed subsequently, and we had to discontinue the
valproic acid and lamotrigine. Ultimately, she was maintained on
phenobarbital (IM, 600 mg/d) and topiramate (200 mg/d/os) and the
clinical and EEG SE persisted. Follow-up image studies including
diffusion weighted images (DWI) and ﬂuid-attenuated inversion
recovery images (FLAIR) disclosed an edematous change with a faint
bright signal on the left frontal cortex after prolonged seizures
(Fig. 2a and b), which was not enhanced by contrast medium.
Intravenous ketamine was added on the ninth day with the
family’s consent. The initial dose of ketamine was 1.5 mg/kg IV
bolus continuously infused with a gradual dose titration from
0.05 mg/kg/h to 0.4 mg/kg/h. The SE pictures on EEG resolved
Fig. 2. (a, b) Axial diffusion weighted image (DWI, b value 1000) and ﬂuid-
attenuated inversion recovery image (FLAIR) 4 days after admission showed slightly
high signals and swelling involving the left anterior frontal area, and resolution of
subdural hematoma at the right high parietal area.
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the left hemisphere and diffuse theta rhythms on the right
hemisphere (Fig. 1c). The patient woke and was able to move her
limbs weakly when the total dose of ketamine reached 2000 mg.
The infusion rate was weaned off when the total given dose was
2500 mg (about 50 mg/kg), and the respirator was disconnected
smoothly. After removing the endotracheal tube, she was
maintained with phenobarbital (180 mg/d/os) and topiramate
(200 mg/d/os), and there were still brief complex partial seizures
noted with durations of about 1–2 min about 2–3 times each day.
At the same time, she was found to be suffering from
bronchopneumonia related to the long hospital stay. Unfortunate-
ly, she gradually lapsed into a stupor with PLEDs reoccurring on
EEG 6 days after discontinuing ketamine (Fig. 1d). We assumed
that the rebound status epilepticus was provoked by nosocomial
infection and inadequate control with oral antiepileptics. Valproic
acid (IV, maximal dose, 1600 mg/d) was infused immediately, and
oral levetiracetam (2000 mg/d/os) was again tried but in vain. Both
the clinical complex partial status epilepticus and PLEDs on EEG
continued, and elevated liver enzymes were detected again 3 days
after valproic acid treatment. A broad-spectrum antibiotic was
substituted, and the dosage of antiepileptics was raised (pheno-
barbital, 400 mg/d IM, and topiramate, 300 mg/d per os). This time,we had to give up intravenous anesthetics to avoid reintubation on
her family’s request, and we decided to add oral ketamine (50 mg
twice daily) via a nasogastric tube. Both the clinical SE and EEG SE
began to improve from the third day of oral ketamine therapy. The
EEG regained diffuse theta waves on the left and right hemispheres
(Fig. 1e) when the total oral ketamine dose reached 1500 mg. Her
condition and EEG remained stable after the total given dose
reached 2000 mg, and oral ketamine was completely withdrawn
shortly thereafter. No complex partial seizures were observed
under the combination treatment of phenobarbital (180 mg/d/os)
and topiramate (200 mg/d/os). The patient was discharged
smoothly after her systemic infection and physical condition
improved.
3. Discussion
Nonconvulsive status epilepticus is well known to be hetero-
geneous with diverse etiologies, different seizure subtypes, and
varied prognosis. There is a common consensus that NCSE should
be treated promptly and effectively to avoid brain damage or
further evolution into generalized convulsive state. Because the
diagnosis and treatment are often delayed, some cases become
refractory status epilepticus. In this situation, the use of anesthetic
agents as recommended in convulsive SE treatment is sometimes
questionable.10 The decision is difﬁcult, especially when the
patients with refractory NCSE have a stable hemodynamic
condition because invasive procedures including intubation and
ventilator support are inevitable when GABAergic anesthetics are
added.11 Therefore anesthetic treatment in refractory NSCE is
usually deferred, and the seizures may become pharmacoresistant.
The iatrogenic problems ensue when GABAergic anesthetics are
used over a period of time.
Electroencephalography is imperative in diagnosing NCSE.1,2,12
EEG with NCSE is typically documented with repetitive generalized
or focal spikes, polyspikes, or spike-slow wave complexes, and some
show rhythmic slow waves with evolution in voltage or frequen-
cy.9,13–16 Characteristically, the EEG ictal pictures improve after
lorazepam or anticonvulsant treatments. In our case, EEG showed
continual PLED activities with periodic polyspikes and slow wave
complexes occurring every 1–2 s, which were regarded as ictal
during the whole disease course. The PLEDs resolved when her
clinical condition improved. PLEDs are usually seen in acute
unilateral or localized lesions such as infarcts, encephalitis and
tumors, and the clinical picture is often complicated with conscious
change. Over 80% of patients with PLEDs have been reported to have
seizures during acute illness.17 It is questionable whether PLEDs
represent an ictal period, ictal–interictal continuum or just a
transitional state of cortical irritability if acute structural lesions
exist, and whether PLEDs are diagnostic in patients with NCSE is still
under debate.2,12 EEG is also important in surveying the treatment
effects. As in our case, in the varying degrees of burst–depression
induced by different GABAergic anesthetics, the focal epileptic
discharges persisted even in the brief burst periods. The persistent
epileptic activities on EEG implied that the GABAergic anesthetics
were ineffective after prolonged seizures. It was evidenced that
every time the anesthetic anticonvulsants were stopped, both
clinical SE and EEG SE reappeared.
It has been proven that after repetitive seizures, GABAA
receptors undergo internalization into the cells and decrease in
number in the synaptic membrane, and in contrast NMDA
receptors are recruited into the membrane.6–8 According to this
phenomenon in self-sustaining SE, combining therapy with NMDA
antagonists to correct the imbalanced neuronal transmission is
reasonable.18–20 Ketamine, which binds noncompetitively to the
phencyclidine site of the NMDA receptor, is a commercially
available NMDA antagonist. The synergistic effects on refractory SE
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combination with anesthetics modulating GABAergic recep-
tors.13,14,16,21,22 Because there is no consensus on intravenous
ketamine treatment and protocol in malignant SE, the treatment in
our elderly patient was modiﬁed from the recommendations
provided by Wasterlain et al. and reports on young adult
cases.4,13,15,16,23 After a bolus dose and then a low steady infusion
dose, the persistent PLEDs on the patient’s EEG gradually
disappeared. However, there were still several complex partial
seizures observed daily when IV ketamine was stopped, and the
patient suffered from another systemic infection.
The patient’s rebound SE was diagnosed rapidly under close
clinical and EEG monitoring. We assumed that the relapse was
provoked by uncontrolled systemic infection and inadequate oral
antiepileptics. This time, the similar pharmacoresistant situation
was treated promptly. We found that oral ketamine therapy
offered the same cumulative therapeutic effect, which was as
remarkable as the intravenous route.24 Oral ketamine has been
used as an analgesic adjuvant in a variety of chronic pain
syndromes for years, and the analgesic effect is primarily based
on the antagonism of NMDA receptors.25 Although the bioavail-
ability of ketamine given orally is only 16%, its primary active
metabolite, norketamine, is also an NMDA antagonist.26,27
Norketamine has lesser afﬁnity to NMDA receptors, but contrib-
utes signiﬁcantly to the clinical effects, especially following oral
administration.
Ketamine has lesser suppressing effects in respiration and
anesthesia, but is known to have psychomimetic side effects and
probable neurotoxicity at high doses. In our case, no signiﬁcant
neurotoxicity was observed, although the patient was elderly and
partially neurologically handicapped.
In conclusion, ketamine was effective and safe in controlling
refractory and malignant NCSE in our elderly patient. If intrave-
nous ketamine is not suitable under the invasive procedures on the
respiratory tract, oral administration of ketamine is an effective
alternative.
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